These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
20 related articles for article (PubMed ID: 16253502)
1. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Sehn LH; MacDonald D; Rubin S; Cantin G; Rubinger M; Lemieux B; Basi S; Imrie K; Gascoyne RD; Sussman J; Chen BE; Djurfeldt M; Shepherd L; Couban S; Crump M J Clin Oncol; 2011 Sep; 29(25):3396-401. PubMed ID: 21810681 [TBL] [Abstract][Full Text] [Related]
2. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma. Hagenbeek A; Eghbali H; Monfardini S; Vitolo U; Hoskin PJ; de Wolf-Peeters C; MacLennan K; Staab-Renner E; Kalmus J; Schott A; Teodorovic I; Negrouk A; van Glabbeke M; Marcus R J Clin Oncol; 2006 Apr; 24(10):1590-6. PubMed ID: 16575010 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762 [TBL] [Abstract][Full Text] [Related]
5. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. Link BK; Martin P; Kaminski MS; Goldsmith SJ; Coleman M; Leonard JP J Clin Oncol; 2010 Jun; 28(18):3035-41. PubMed ID: 20458031 [TBL] [Abstract][Full Text] [Related]
6. Issues for the future development of fludarabine phosphate. Cheson BD Semin Oncol; 1990 Oct; 17(5 Suppl 8):71-8. PubMed ID: 1699286 [TBL] [Abstract][Full Text] [Related]
7. Fludarabine phosphate-CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: a dose-finding study. Soubeyran P; Monnereau A; Eghbali H; Soubeyran I; Kind M; Cany L; Buy E; Guibon O; Hoerni B Eur J Cancer; 2005 Nov; 41(17):2630-6. PubMed ID: 16253502 [TBL] [Abstract][Full Text] [Related]
8. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062 [TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]